GH Research PLC (NASDAQ:GHRS) Given Average Rating of “Buy” by Analysts

Shares of GH Research PLC (NASDAQ:GHRS) have earned a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is $30.86.

Several analysts have weighed in on the company. Royal Bank of Canada began coverage on GH Research in a research note on Friday, March 7th. They set an “outperform” rating and a $31.00 price target on the stock. Stifel Nicolaus increased their price target on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Cantor Fitzgerald began coverage on shares of GH Research in a research note on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Finally, Guggenheim started coverage on shares of GH Research in a report on Thursday, March 13th. They set a “buy” rating and a $32.00 target price for the company.

GH Research Stock Down 0.3 %

GHRS opened at $11.03 on Tuesday. The company has a market cap of $573.87 million, a P/E ratio of -13.96 and a beta of 0.94. The firm’s 50-day moving average price is $11.80 and its 200-day moving average price is $9.37. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. On average, research analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. grew its position in GH Research by 1.3% during the third quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after buying an additional 85,000 shares during the period. Lynx1 Capital Management LP boosted its stake in shares of GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Diadema Partners LP acquired a new stake in shares of GH Research during the 4th quarter valued at about $711,000. Woodline Partners LP increased its stake in shares of GH Research by 112.0% in the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock valued at $553,000 after purchasing an additional 41,711 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in GH Research by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after purchasing an additional 3,092 shares during the period. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).